Zealand Pharma A/S was founded in and is a biotechnology company focused on the discovery, design and development of innovative peptide based medicines. We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim.
Quote | Zealand Pharma A/S (NASDAQ:ZEAL)
Last: | $17.59 |
---|---|
Change Percent: | -2.5% |
Open: | $18.03 |
Close: | $17.59 |
High: | $18.07 |
Low: | $17.47 |
Volume: | 2,157 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Zealand Pharma A/S (NASDAQ:ZEAL)
Press release – No. 3 / 2023 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference Copenhagen, Denmark, March 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the d...
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a solid financial position Positive results achieved for petrelintide in 6-week Phas...
Message Board Posts | Zealand Pharma A/S (NASDAQ:ZEAL)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Zealand Pharma A/S Company Name:
ZEAL Stock Symbol:
NASDAQ Market:
Press release – No. 3 / 2023 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference Copenhagen, Denmark, March 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the d...
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a solid financial position Positive results achieved for petrelintide in 6-week Phas...
Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis Survodutide has potential to become best-in...